Literature DB >> 24198229

Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis.

C Veyrat-Durebex1, P Corcia, A Dangoumau, F Laumonnier, E Piver, P H Gordon, C R Andres, P Vourc'h, H Blasco.   

Abstract

Amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, is fatal for most patients less than 3 years from when the first symptoms appear. The aetiologies for sporadic and most familial forms of ALS are unknown, but genetic factors are increasingly recognized as causal in a subset of patients. Studies of disease physiology suggest roles for oxidative stress, glutamate-mediated excitotoxicity or protein aggregation; how these pathways interact in the complex pathophysiology of ALS awaits elucidation. Cellular models are being used to examine disease mechanisms. Recent advances include the availability of expanded cell types, from neuronal or glial cell culture to motoneuron-astrocyte co-culture genetically or environmentally modified. Cell culture experiments confirmed the central role of glial cells in ALS. The recent adaptation of induced pluripotent stem cells (iPSC) for ALS modeling could allow a broader perspective and is expected to generate new hypotheses, related particularly to mechanisms underlying genetic factors. Cellular models have provided meaningful advances in the understanding of ALS, but, to date, complete characterization of in vitro models is only partially described. Consensus on methodological approaches, strategies for validation and techniques that allow rapid adaptation to new genetic or environmental influences is needed. In this article, we review the principal cellular models being employed in ALS and highlight their contribution to the understanding of disease mechanisms. We conclude with recommendations on means to enhance the robustness and generalizability of the different concepts for experimental ALS.

Entities:  

Mesh:

Year:  2013        PMID: 24198229     DOI: 10.1007/s12035-013-8573-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  186 in total

Review 1.  [Mechanisms of deregulated response to hypoxia in sporadic amyotrophic lateral sclerosis: a clinical study].

Authors:  C Moreau; D Devos; P Gosset; V Brunaud-Danel; A-B Tonnel; P Lassalle; L Defebvre; A Destée
Journal:  Rev Neurol (Paris)       Date:  2009-08-05       Impact factor: 2.607

2.  Oxidative and excitotoxic insults exert differential effects on spinal motoneurons and astrocytic glutamate transporters: Implications for the role of astrogliosis in amyotrophic lateral sclerosis.

Authors:  Chrissandra J Zagami; Philip M Beart; Nicole Wallis; Phillip Nagley; Ross D O'Shea
Journal:  Glia       Date:  2009-01-15       Impact factor: 7.452

3.  Angiogenin protects motoneurons against hypoxic injury.

Authors:  J Sebastià; D Kieran; B Breen; M A King; D F Netteland; D Joyce; S F Fitzpatrick; C T Taylor; J H M Prehn
Journal:  Cell Death Differ       Date:  2009-05-15       Impact factor: 15.828

4.  A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis-linked SOD1 mutants.

Authors:  Takao Fujisawa; Kengo Homma; Namiko Yamaguchi; Hisae Kadowaki; Naomi Tsuburaya; Isao Naguro; Atsushi Matsuzawa; Kohsuke Takeda; Yuji Takahashi; Jun Goto; Shoji Tsuji; Hideki Nishitoh; Hidenori Ichijo
Journal:  Ann Neurol       Date:  2012-11       Impact factor: 10.422

5.  Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration.

Authors:  Zihui Xu; Mickael Poidevin; Xuekun Li; Yujing Li; Liqi Shu; David L Nelson; He Li; Chadwick M Hales; Marla Gearing; Thomas S Wingo; Peng Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-03       Impact factor: 11.205

6.  TDP-43 dimerizes in human cells in culture.

Authors:  Yuki Shiina; Kunimasa Arima; Hiroko Tabunoki; Jun-ichi Satoh
Journal:  Cell Mol Neurobiol       Date:  2009-12-31       Impact factor: 5.046

7.  Influence of muscle wasting on oral glucose tolerance testing.

Authors:  R T Moxley; R C Griggs; G B Forbes; D Goldblatt; K Donohoe
Journal:  Clin Sci (Lond)       Date:  1983-06       Impact factor: 6.124

8.  Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress.

Authors:  Mark R Cookson; Fiona M Menzies; Philip Manning; Christopher J Eggett; Denise A Figlewicz; Calum J McNeil; Pamela J Shaw
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2002-06

9.  Lead exposure stimulates VEGF expression in the spinal cord and extends survival in a mouse model of ALS.

Authors:  Ana G Barbeito; Laura Martinez-Palma; Marcelo R Vargas; Mariana Pehar; Nelly Mañay; Joseph S Beckman; Luis Barbeito; Patricia Cassina
Journal:  Neurobiol Dis       Date:  2009-11-13       Impact factor: 5.996

10.  Enrichment of spinal cord cell cultures with motoneurons.

Authors:  D K Berg; G D Fischbach
Journal:  J Cell Biol       Date:  1978-04       Impact factor: 10.539

View more
  9 in total

1.  A new method for generating high purity motoneurons from mouse embryonic stem cells.

Authors:  Dylan A McCreedy; Chelsea R Brown; Jessica C Butts; Hao Xu; James E Huettner; Shelly E Sakiyama-Elbert
Journal:  Biotechnol Bioeng       Date:  2014-06-04       Impact factor: 4.530

Review 2.  Induced pluripotent stem cells from ALS patients for disease modeling.

Authors:  Jean-Philippe Richard; Nicholas J Maragakis
Journal:  Brain Res       Date:  2014-09-16       Impact factor: 3.252

3.  Histological-MRI correlation in the primary motor cortex of patients with amyotrophic lateral sclerosis.

Authors:  Mark D Meadowcroft; Nathan J Mutic; Don C Bigler; Jian-Li Wang; Zachary Simmons; James R Connor; Qing X Yang
Journal:  J Magn Reson Imaging       Date:  2014-02-26       Impact factor: 4.813

Review 4.  Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration.

Authors:  C Maurel; A Dangoumau; S Marouillat; C Brulard; A Chami; R Hergesheimer; P Corcia; H Blasco; C R Andres; P Vourc'h
Journal:  Mol Neurobiol       Date:  2018-01-10       Impact factor: 5.590

5.  Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis.

Authors:  Charlotte Veyrat-Durebex; Philippe Corcia; Eric Piver; David Devos; Audrey Dangoumau; Flore Gouel; Patrick Vourc'h; Patrick Emond; Frédéric Laumonnier; Lydie Nadal-Desbarats; Paul H Gordon; Christian R Andres; Hélène Blasco
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

Review 6.  Neurofilaments: neurobiological foundations for biomarker applications.

Authors:  Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

7.  NSC-34 Motor Neuron-Like Cells Are Unsuitable as Experimental Model for Glutamate-Mediated Excitotoxicity.

Authors:  Blandine Madji Hounoum; Patrick Vourc'h; Romain Felix; Philippe Corcia; Franck Patin; Maxime Guéguinou; Marie Potier-Cartereau; Christophe Vandier; Cédric Raoul; Christian R Andres; Sylvie Mavel; Hélène Blasco
Journal:  Front Cell Neurosci       Date:  2016-05-09       Impact factor: 5.505

Review 8.  Bile Acids in Neurodegenerative Disorders.

Authors:  Hayley D Ackerman; Glenn S Gerhard
Journal:  Front Aging Neurosci       Date:  2016-11-22       Impact factor: 5.750

9.  Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration.

Authors:  Chrystian J Alves; Rafael Dariolli; Frederico M Jorge; Matheus R Monteiro; Jessica R Maximino; Roberto S Martins; Bryan E Strauss; José E Krieger; Dagoberto Callegaro; Gerson Chadi
Journal:  Front Cell Neurosci       Date:  2015-08-04       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.